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Background: Clozapine is uniquely effective in treatment-resistant psychosis but remains 24 
underutilised, partly due to psychotic symptoms leading to non-adherence to oral medication. An 25 
intramuscular (IM) formulation is available in the UK but outcomes remain unexplored. 26 
 27 
Aims: This was a retrospective clinical effectiveness study of IM clozapine prescription for treatment 28 
initiation and maintenance in treatment-resistant psychosis over a 3-year period. 29 
 30 
Methods: Successful initiation of oral clozapine after IM prescription was the primary outcome. 31 
Secondary outcomes included all-cause clozapine discontinuation two years following initiation, and 32 
one year after discharge. Discontinuation rates were compared with a cohort only prescribed oral 33 
clozapine. Propensity scores were used to address confounding-by-indication. 34 
   35 
Results: Among 39 patients prescribed IM clozapine, 19 received at least one injection, while 20 36 
accepted oral when given an enforced choice between oral and IM clozapine. Thirty-six (92%) 37 
successfully initiated oral clozapine after IM prescription; 3 never transitioned to oral. Eight 38 
discontinued oral clozapine during the two-year follow-up, versus 83/162 in the comparator group 39 
(discontinuation rates of 24% and 50% respectively). Discontinuation rates at one-year post-40 
discharge were 21%, compared to 44% in the comparison group. IM clozapine prescription was 41 
associated with a non-significantly lower hazard of discontinuation two-years after initiation and one-42 
year after discharge (HR0.39,95%CI 0.14–1.06; HR0.37,95%CI 0.11-1.24). The only reported 43 
adverse event specific to the IM formulation was injection site pain and swelling.  44 
 45 
Conclusions: IM clozapine prescription allowed transition to oral maintenance in a cohort initially 46 
non-adherent. Discontinuation rates were similar to patients only prescribed oral clozapine and 47 
comparable to existing literature.  48 




Clozapine has been considered the gold-standard for treatment-resistant psychotic disorders since 53 
the 1980s (1). It demonstrates a 50 to 75% response rate among those who fail to achieve remission 54 
with conventional first- or second-generation antipsychotics (2). Clozapine is associated with better 55 
long-term outcomes than other antipsychotics or no treatment, including lower long-term all-cause 56 
mortality rates (3), reduced violent offending (4) and readmission rates (5). Despite superior efficacy, 57 
clozapine remains significantly underutilized and its initiation is often substantially delayed. The 58 
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study reported that only 14 to 50% 59 
of eligible patients were treated with clozapine (6). Furthermore, data from the United Kingdom (UK) 60 
shows that clozapine initiation is typically delayed by approximately 4 years (7).  61 
 62 
One common problem occurs when treatment-resistant patients are not able to accept clozapine or 63 
associated blood tests due to symptoms of acute psychosis, including impaired insight and 64 
delusional beliefs. Although the Mental Health Act (MHA) in England and Wales gives the legal 65 
authority to administer involuntary drug treatment and ancillary investigations, including blood tests 66 
to support clozapine use (Mental Health Act. Nottingham: CQC; 2008), most patients who require 67 
but are non-adherent to antipsychotics are prescribed long-acting injections, due to the practical 68 
difficulties of enforcing oral treatment.  However, since clozapine is not available as a long acting 69 
injection, an unwillingness to take the oral form of clozapine has hitherto precluded clozapine 70 
treatment. While compulsory administration of medication is not uncommon in psychiatric care, this 71 
is rarely employed with clozapine treatment, with only a few facilities worldwide reporting the use of 72 
nasogastric (8) and intramuscular (IM) clozapine (9,10,11,12,13).  73 
 74 
In this study, we present our 3-year experience with short acting IM clozapine in the South London 75 





Study design 81 
 82 
Observational data from SLaM were collected to follow-up a cohort of patients prescribed IM 83 
clozapine as a short-term strategy to initiate oral clozapine. Our aim was to evaluate its potential 84 
value in initiating and maintaining clozapine in patients initially reluctant to take oral clozapine. 85 
Transition from IM prescription to oral clozapine was the primary outcome. The secondary outcome 86 
was all-cause clozapine discontinuation, a widely used outcome measure in observational studies. 87 
Post-discharge discontinuation rates were investigated in order to assess long-term adherence to 88 
oral medication outside a hospital setting where concordance cannot be prompted and supervised 89 
by healthcare professionals. Finally, we compared all-cause clozapine discontinuation rates with 90 
those of a comparison group of patients started and maintained on oral clozapine, without IM 91 
prescription, while detained under the MHA in SLaM. This analysis was conducted to investigate 92 
whether addressing an initial reluctance to accept clozapine treatment by prescribing the IM 93 
formulation will lead to long-term compliance at rates similar to or different from patients who 94 
accepted oral clozapine from initiation. 95 
 96 
IM clozapine 97 
 98 
The IM clozapine used in this study is manufactured by Apotheek A15® (formerly Brocacef®) in the 99 
Netherlands and was approved by the Drugs and Therapeutics Committee of SLaM NHS Foundation 100 
Trust in 2016. Owing to the need for daily administration, and the large volume that must be injected 101 
to achieve maintenance doses of clozapine, IM clozapine is not suitable as a long-term treatment. 102 
Although there is no upper limit, the protocol suggests not exceeding 14 days of injections; 103 
nonetheless previous data report safe use of IM clozapine for up to 96 days (9).  Therefore, the 104 
SLaM protocol (see Supplementary material 1) allows for IM clozapine as a short-term intervention 105 
to initiate or re-initiate clozapine treatment in patients who refuse oral medication, with a view to 106 
converting to oral clozapine once compliance is achieved. The decision to prescribe IM clozapine is 107 
undertaken on an individual basis and our local protocol states that it must be agreed by a 108 
multidisciplinary team, Director of Pharmacy and a second opinion doctor appointed by the Care 109 
Quality Commission under the provisions of the MHA, 1983. The final decision is driven by a 110 
comprehensive assessment, which includes extensive information gathered from various sources 111 
such as family discussions, capacity assessments and best interest meetings. The latter aims to 112 
reach a decision in the best interest of a patient who is assessed to lack capacity for the decision in 113 
question. 114 
 115 
Once IM clozapine is prescribed, the choice of oral clozapine must be offered at every administration, 116 
and the injection is only administered as a last resort when oral clozapine is refused. The strength 117 
of IM clozapine is 25mg/ml and each ampoule contains 5ml (125mg). Current recommendations, 118 
based on clozapine pharmacokinetics, assume oral bioavailability of clozapine to be approximately 119 
50% of the IM formulation (14). As the injection of larger volumes can be painful, it is suggested that 120 
the maximum volume that can be injected into each site is 4ml (100mg), which gives approximately 121 
equivalent bioavailability as 200mg oral clozapine. For doses greater than 100mg daily, the dose 122 
may be divided and administered into two sites based on individual preference. To minimise the 123 
number of injections, once daily dosing is preferred.  124 
 125 
IM clozapine cohort 126 
 127 
All individuals prescribed IM clozapine between 1st June 2016 and 7th March 2019 in an inpatient 128 
care setting within SLaM were included in the study. They all lacked capacity to treatment. Each 129 
patient prescribed IM clozapine was added to a register and linked to electronic medical notes and 130 
pharmacy dispensing records. Patients were followed-up with regard to concordance to oral 131 
clozapine treatment until clozapine discontinuation or two years after IM clozapine prescription or 132 
31st July 2019, when the data collection ended, whichever occurred sooner. Time to all-cause post-133 
discharge discontinuation was defined as the time from the date of discharge until the date oral 134 
clozapine was stopped, one year of treatment or end of data collection (31st July 2019), whichever 135 
occurred sooner. Treatment discontinuation was defined as a discontinuation for longer than seven 136 
consecutive days, even if clozapine was later re-initiated. 137 
 138 
Patient demographics and clinical data such as the duration of illness, prior use of clozapine and the 139 
date of clozapine initiation, discharge and transition from IM to oral clozapine were collected from 140 
electronic medical records. Global clinical severity was rated retrospectively at IM clozapine 141 
prescription using the Clinical Global Impression Improvement scale (CGI-I) by manual analysis of 142 
patients notes in the electronic medical records by an experienced psychiatrist (CC). Further data 143 
included clozapine injection date(s) and dose(s), and use of restraints. Reasons for clozapine 144 
discontinuation where applicable were obtained from descriptive medical records. Patients who were 145 
discharged from SLaM were followed up through their registered pharmacies responsible for 146 
clozapine supply. A questionnaire was sent to respective pharmacists asking whether the patient 147 
under their care remained on clozapine treatment and, if not, the date and reason for discontinuation.  148 
 149 
Comparison group: historical cohort 150 
 151 
The comparison group included patients with a diagnosis of a treatment-resistant psychotic disorder 152 
(ICD-10: F20–F29) aged between 18 and 65 years old initiated on oral clozapine in a SLaM facility 153 
in routine clinical practice between 1st January 2007 and 31st December 2011. We selected patients 154 
who were initiated on clozapine while detained under the MHA (Section 2, Section 3 or Section 155 
47/49) to represent compulsory treatment in the historical cohort. These data were collected as part 156 
of a previous study investigating reasons for clozapine discontinuation (15) from the Clinical Records 157 
Interactive Search (CRIS) system, an anonymized case register derived from SLaM electronic case 158 
records. Follow-up with regard to continuing clozapine was carried on until clozapine discontinuation 159 
or 2 years after clozapine initiation, whichever occurred sooner. Post-discharge follow-up was 160 
continued from the date of discharge until the date clozapine was stopped or one year of treatment, 161 
whichever occurred sooner. Global clinical severity was rated retrospectively at clozapine 162 
prescription using the CGI-I by manual analysis of the electronic medical records. No information on 163 
the use of restraints was available for the historical cohort.  164 
 165 
Adverse events  166 
 167 
All SLaM patient records were scrutinized for documented adverse events (including when they first 168 
occurred in relation to the initiation date). Adverse events were defined as any unfavourable and 169 
unintended sign, symptom or disease noted on the electronic records, which occurred during use of 170 
IM clozapine or within 3 days from administration, that are not recorded by the manufacturer's 171 
summary product characteristics (https://www.medicines.org.uk/emc/product/4411/smpc).  172 
 173 
Statistical methods 174 
  175 
Statistical analysis was carried out using Stata, version 15 (16). The percentage of patients who 176 
successfully initiated oral clozapine after IM prescription was calculated. Kaplan-Meier survival 177 
curves were used to estimate and graph the time to clozapine discontinuation from IM or oral 178 
clozapine prescription in both the IM cohort and the comparison group respectively. Patients were 179 
followed from the date of first IM clozapine prescription and were censored after 2 years follow up 180 
or 31st July 2019, whichever occurred sooner. All cause discontinuation of oral clozapine was 181 
calculated, and all patients who were prescribed IM clozapine were included, whether or not they 182 
received the drug intramuscularly. After checking proportional hazard assumptions, a Cox regression 183 
was employed to model the association between IM clozapine prescription and clozapine 184 
discontinuation. Propensity scores were used in order to address the issue of confounding-by-185 
indication and a fully adjusted Cox analysis was carried out with the propensity score included as a 186 
covariate. Propensity scores indicate the probability of being prescribed IM clozapine based on 187 
patient characteristics (age, gender, diagnosis, length of illness, CGI at clozapine prescription) and 188 
were calculated using logistic regression. 189 
 190 
A separate survival analysis was set up to model post-discharge clozapine discontinuation rates, 191 
which were graphed using a Kaplan-Meier survival curve in both the IM and comparison group, with 192 
T0 at the date of discharge.  Patients were censored after one-year follow up or 31st July 2019, 193 
whichever occurred sooner. The discontinuation rates in the two groups were analysed using a Cox 194 
regression model adjusted for propensity scores, which were included in the analysis as a covariate. 195 
 196 
Post hoc analysis using Kaplan-Meier survival curves was conducted to evaluate differences in 197 
discontinuation rates after IM prescription between the subgroup of patients who were prescribed 198 
and administered IM clozapine and those who had it prescribed but not administered. Post-hoc Cox 199 
regression analysis was conducted to calculate the hazard of clozapine discontinuation in the two 200 
sub-groups. 201 
 202 
Ethical standards 203 
 204 
This clinical effectiveness study was approved by the Drugs and Therapeutics Committee (DTC) of 205 
the South London and Maudsley NHS Foundation Trust, the locally designated approval committee 206 
for all non-interventional prescribing outcome audits. The local SLaM protocol for the use of IM 207 
clozapine was approved by DTC. 208 
 209 
Ethical approval for the use of CRIS as a research dataset was given by Oxfordshire Research 210 
Ethics Committee C (08/H0606/71). The service-user led CRIS oversight committee granted 211 
permission for the use of a previously identified anonymised cohort of patients commencing oral 212 
clozapine to provide the comparison group data. Informed consent was not required as CRIS is an 213 





Patient Characteristics: IM clozapine cohort   219 
 220 
Data were available for 39 inpatients with a treatment-resistant psychotic disorder who had been 221 
prescribed IM clozapine. Of these, 19 (49%) were administered at least one injection (median 2, 222 
range 1 – 56), while 20 (51%) preferred to receive oral clozapine when offered the enforced choice 223 
between oral and IM administration. Of the patients who received more than one injection, 7 (50%) 224 
were administered consecutively and 7 (50%) received IM intermittently with oral clozapine. 32 225 
patients (82% of our sample) had previously taken clozapine. Cohort characteristics are presented 226 
in Table 1. Table 2 summarises characteristics of IM clozapine administrations in our sample. 227 
 228 
Among the 19 patients who received IM clozapine, the median maximum daily IM dose was 75 mg 229 
(range 6.25 – 200mg), equivalent to 150mg of oral clozapine. Most patients (n=16, 84%) received 230 
the injection(s) during the titration period; either from the first dose (n=11, 58%) or after refusing later 231 
doses (n=5, 26%). Manual restraints by nursing staff were used in nine patients (47%) with a median 232 
of zero and a mean of two restraints per patient (0 restraints: 10 patients; 1 restraint: 5 patients; >1 233 
restraint: 4 patients). No mechanical restraints were used. The most common adverse event 234 
associated with IM formulation was swelling at the injection site, which occurred in the three patients 235 
who had more than 29 injections (16%). Other side effects reported in the patients’ notes were 236 
drowsiness in two patients (10%), urinary incontinence (one patient, 5%) and neutropenia (1 patient, 237 
5%). No side effects associated with physical restraints were reported in the electronic notes, 238 
although psychological consequences were not explicitly investigated. 239 
 240 
Patient Characteristics: Historical cohort   241 
 242 
The comparison group included 162 patients who started oral clozapine while admitted to a SLaM 243 
hospital under the MHA. They all fulfilled the criteria for a treatment-resistant psychotic disorder, and 244 
their characteristics are summarized in Table 1. 245 
 246 
Transition from IM to oral clozapine and discontinuation rates  247 
 248 
In total, 36 patients (92%) eventually started oral clozapine after being prescribed the IM formulation. 249 
Among those who received at least one injection, 16 (84%) were later switched to oral. The 250 
remaining three either continued to refuse oral clozapine despite IM administrations or discontinued 251 
IM clozapine due to adverse effects (neutropenia, recurrent pneumonia). The median number of 252 
days of injection before transition to oral was 2 (range 1-47). 253 
 254 
In the IM cohort, median follow-up was 694 (IQR 481 – 720) days from IM prescription date and 296 255 
(IQR 0 – 365) days from discharge date. In the comparison group, mean follow up was 720 days 256 
from the date of clozapine initiation and 365 days from discharge. In the subgroup of patients who 257 
were prescribed and administered IM clozapine median follow up was 509 (IQR 302 – 720) days 258 
from prescription and 236 (IQR 0 – 365) days from discharge, while in the subgroup of patients who 259 
were prescribed but not administered IM clozapine mean follow up was 683 (IQR 534 – 720) days 260 
from prescription and 287 (IQR 0 – 365) days from discharge. 261 
 262 
Fig. 1A displays a Kaplan-Meier survival curve for the clozapine discontinuation rates after clozapine 263 
prescription in the cohort of patients who were prescribed IM clozapine and in the comparison group. 264 
Discontinuation rates at two-year follow up were lower in the cohort of patients who were initially 265 
prescribed IM clozapine than in the comparison group (24% and 50% respectively), with a reduced 266 
hazard of clozapine discontinuation (HR 0.39, 95% CI 0.19 – 0.80) although this became non-267 
significant after the model was adjusted for propensity scores (HR 0.39, 95% CI 0.14 – 1.06). In a 268 
post-hoc analysis, higher discontinuation rates were found in those who received the injection 269 
compared to those who chose to receive oral clozapine after being offered the enforced choice 270 
between the two formulations (52% and 6% respectively; HR 10.34, 95% CI 1.26 - 84.70). The 271 
Kaplan-Meier survival curve is shown in Fig. 1B. Table 3 summarizes the results of the Cox 272 
regression analyses. 273 
 274 
Data were available after discharge for 29 of the IM patients (74%; 5 of which had received at least 275 
1 injection) as the remaining 10 (26%) were still in hospital at the end of the study. Twenty-two (76% 276 
of those discharged) patients were maintained on oral clozapine until the end of follow-up; in the 277 
comparison group 81/162 patients remained on clozapine one year after discharge. Among the 278 
seven patients who were clozapine-naïve at IM prescription, three (43%) were still on oral clozapine 279 
at the end of follow-up.  280 
 281 
Patients included in the post-discharge survival analysis are shown in Fig. 2. Discontinuation rates 282 
at one year after discharge for the IM cohort and the comparison group were 21% and 44% 283 
respectively (Fig. 1C). Fig. 1D graphs the post-hoc survival analysis for the subgroup of patients who 284 
were administered and those who were not administered IM clozapine. Compared to oral, IM 285 
clozapine prescription was associated with a non-significantly reduced risk of clozapine 286 
discontinuation after discharge after adjusting for propensity scores (HR 0.37, 95% CI 0.11 - 1.24). 287 
Post-hoc Cox regression analysis showed an increased risk of clozapine discontinuation after 288 
discharge in the subgroup of patients who were administered IM clozapine compared to those 289 
prescribed but not administered IM clozapine, although this was not statistically significant (adjusted 290 
HR 5.35, 95% CI 0.62 - 45.87).  291 
 292 
In the entire cohort of 39 patients, eight (20%) discontinued clozapine treatment during the follow-293 
up period. Four (10%) were due to non-adherence or unknown reasons and four due to adverse 294 
effects (10%) unrelated to the IM formulation but rather to clozapine’s established adverse effect 295 
profile (neutropenia, recurrent pneumonia).  296 
 297 
On a practical level, the majority of patients who received IM clozapine were administered less than 298 
10 injections (n=13; 68%), with a discontinuation rate of 39% after 2 years of treatment. However, 299 
amongst the 6 patients who received more than 10 injections, two (33%) switched to oral clozapine 300 
and remained on it at the end of follow-up, whilst four discontinued it. The maximum number of 301 
injections administered before successful transition to oral treatment was 47.  302 
 303 
Among the nine patients who required manual restraints during IM clozapine administration, seven 304 
remained on clozapine at follow-up, whilst two discontinued, one of which never agreed to transition 305 





In this retrospective clinical effectiveness study of patients prescribed IM clozapine, 92% of patients 311 
were successfully initiated on oral clozapine after IM prescription after a median of two IM 312 
administrations. Of patients with sufficient follow-up data, 76% remained on clozapine at two years 313 
from initiation. Clozapine discontinuation rates at two-year follow up were similar to a comparison 314 
group of patients who were prescribed only oral clozapine under the MHA in routine clinical practice. 315 
Correspondingly, clozapine discontinuation rates of 21% were observed at one-year follow-up post-316 
discharge. This is at the lower end of that shown in previous studies, which demonstrate clozapine 317 
discontinuation rates between 16 and 66% across various countries (17). 318 
 319 
Clozapine has consistently been shown to provide superior therapeutic benefits in treatment-320 
resistant psychotic disorders (1) and should therefore be offered to all patients that meet these 321 
criteria. NICE guidelines highlight the importance of involving patients in decisions about the choice 322 
of medication (18). Nonetheless, some people diagnosed with a psychotic disorder lack insight and 323 
capacity to make an informed decision about optimal treatment options, particularly during acute 324 
illness, and may therefore make a non-capacitous decision to decline medication. Moreover, patients 325 
may be non-adherent as a direct response to delusional beliefs. There is compelling evidence to 326 
suggest that patients’ refusal of clozapine in treatment-resistant psychotic disorders may have a 327 
significant negative impact on their long-term outcomes, and in the best interest of selected cases, 328 
enforced treatment may be the most appropriate option.  329 
 330 
Presently, few naturalistic studies have demonstrated the potential of IM clozapine in initiating 331 
treatment, with a total enrolment of approximately 100 patients (9,10,11,12,13). To our knowledge, 332 
this is the largest study in the UK to report the use of short-acting IM clozapine for treatment initiation 333 
and maintenance in patients with a treatment-resistant psychotic disorder. Our study further adds to 334 
the evidence for IM clozapine as a viable tool to allow patients whose illness is compromising their 335 
capacity to consent to appropriate treatment for their resistant psychotic disorder to access and 336 
benefit from clozapine.  337 
 338 
Post-discharge discontinuation rates were as good as, or better than, a comparison group prescribed 339 
only oral clozapine. This suggests that the prescription of IM clozapine may achieve long-term clinical 340 
improvement and adherence to oral medication, even in those patients who are initially reluctant to 341 
engage with clozapine treatment, and that this is maintained even in a less restrictive setting. 342 
Consistent with previous studies (9,11,13), our data found no evidence that IM clozapine differs 343 
markedly from oral clozapine tolerability and adverse effects, with the one reported adverse event 344 
related to its formulation being swelling at the injection site. However, the lack of additional side 345 
effects reported may be attributed to its short-term use, often during titration and therefore at low 346 
doses, and this study was not powered nor designed to assess safety.  347 
 348 
In the observational cohort, over half of those who had been prescribed IM clozapine chose to accept 349 
oral clozapine after being offered the choice between the two formulations. This finding is in line with 350 
an observational study by Hoge et al., (20), according to which drug refusal developed into voluntary 351 
acceptance of treatment by most patients. Although preliminary, our data on discontinuation rates 352 
among those who did not require IM administrations is in line with previous findings (9,11) that the 353 
mere prescription of IM clozapine can increase adherence to clozapine without the need of IM 354 
administration.  Post hoc analysis also showed that those patients who accepted oral clozapine when 355 
offered the IM had lower discontinuation rates compared to patients who declined oral and were 356 
administered IM clozapine. Although this result should be interpreted with caution due to small 357 
numbers, this may be attributed to a more entrenched attitude towards medication in the latter 358 
subgroup. Nevertheless, future qualitative work is required to understand the decision-making 359 
process underpinning a patient’s decision to accept oral treatment when there is a choice between 360 
IM and oral dispensation. 361 
 362 
Enforcement of treatment in psychiatry remains an ethically and clinically contentious practice. 363 
Previous literature has raised questions about the risks and benefits of enforcing clozapine treatment 364 
(22). This debate is ongoing, and it is beyond the scope of this article. However, in an investigation 365 
on patients’ perception towards their involuntary admission, O’Donoghue et al., (23) found that prior 366 
to discharge 72% of patients reported admission to have been necessary and almost 80% felt that 367 
the received treatment had been beneficial. Furthermore, previous studies have demonstrated 368 
improvement in inpatients with schizophrenia, irrespective of whether they received treatment 369 
voluntarily or involuntarily (24). Of interest, patients treated involuntarily tended to show even greater 370 
symptom improvement than voluntary patients (24). Consistent with our findings, a recent small-371 
scale study in the UK demonstrated positive outcomes with compulsory clozapine treatment by 372 
nasogastric administration. Nevertheless, the IM route remains well-established in clinical practice 373 
and avoids the considerably more invasive and distressing nature of nasogastric administration and 374 
its greater resource requirements (8).  375 
 376 
While our sample is too small to draw any firm conclusions, our findings may justify safely persisting 377 
with IM clozapine to achieve transition to oral, despite a prolonged refusal of oral treatment. 378 
Nevertheless, individual-based decisions are paramount to ensure the best interest of every patient.  379 
In our study, the use of manual restraints by nursing staff did not appear to influence clozapine 380 
discontinuation rates. Clozapine treatment has been shown to demonstrate a reduction in incidents 381 
of aggression and subsequent restraints, but whether this is comparable with IM administration 382 
remains unanswered. Furthermore, due to the lack of a formal evaluation, the psychological impact 383 
of restraint on both patients and nursing could not be investigated in our study. 384 
 385 
Our experience also suggests IM clozapine can be used to achieve oral clozapine initiation and avoid 386 
treatment interruption when used both consecutively and intermittently with oral clozapine. Previous 387 
authors have shown clozapine to be a cost-effective therapy in TRS (21), it is likely that an economic 388 
evaluation will demonstrate that IM clozapine prescription is highly cost-effective, especially in light 389 
of the absence of alternative treatments for this population.  390 
 391 
Despite the encouraging evidence generated from our study, it must be emphasized that those who 392 
declined treatment do not form a homogenous group and might have done so for a variety of reasons 393 
that warrant further examination before any actions are taken. Similarly, different factors could have 394 
played a role in favouring a transition from IM to oral clozapine, such as clinician-patient relationship 395 
or familiarity with nursing staff providing medication. In addition, relevant differences were observed 396 
between the two study groups. The patients offered IM clozapine had greater severity (CGI: mean 397 
6.18, SD 0.45) and longer duration of illness (mean years 21.32, SD 11.18) than the comparison 398 
population (CGI: 5.35 ± 0.64; DOI: 9.42 ± 8.01). However, previous studies on patients with a 399 
schizophrenia-spectrum disorder have suggested that those who refuse treatment tend to be more 400 
symptomatic and with worse functioning than those who agree to treatment (25). Furthermore, only 401 
18% of our patients were clozapine naïve at IM clozapine prescription, which might reflect the fact 402 
that IM clozapine is more likely to be recommended in patients with a previous good response to 403 
clozapine. Nevertheless, previous work has demonstrated clinical effectiveness in clozapine-naïve 404 
patients (11).  405 
 406 
 407 
Limitations and future research  408 
 409 
The most important limitation of our study is the small sample size; however, this is consistent 410 
with previous studies evaluating IM clozapine use (9,11,13). This limits the interpretability of our 411 
results, as evidenced by the fairly large confidence intervals around the results. The limited number 412 
of patients included in the study has also prevented us from conducting further post-hoc analysis 413 
which could be useful in order to identify specific sub-groups of patients who could benefit from IM 414 
clozapine administration. Secondly, as follow-up data collection ended in July 2019, 26% (n=10) of 415 
patients could not be followed up after discharge since they were still in hospital. In addition, not 416 
all patients who were discharged had sufficient follow-up, as they were in the community for less 417 
than one year at data collection. Furthermore, the naturalistic nature of our study meant that 418 
clozapine continuation post-discharge was confirmed by prescription refills of oral clozapine and 419 
adherence to haematological monitoring requirements opposed to the more objective method of 420 
measuring serum clozapine levels. Equally, the quality of data available for reasons for clozapine 421 
discontinuation were limited to the information provided in electronic clinical record systems by the 422 
patient’s clinical team. Our study needs to be replicated prospectively in a larger sample 423 
size possibly with a longer follow-up period.  424 
 425 
Another limitation lies in the comparator group. Patients who are prescribed IM clozapine are 426 
intrinsically different from those who accept oral clozapine, being less compliant and willing to accept 427 
any kind of treatment. Our comparator group differed from the cohort in age, and they had longer 428 
length of illness and higher CGI at clozapine initiation. We addressed this confounding-by-indication 429 
by calculating and adjusting for propensity scores in the Cox regression analyses, although some 430 
potential confounders may not have been measured and hence not included in the adjustment. 431 
Nonetheless, as the IM clozapine cohort included more severely unwell patients than the historical 432 
comparator, this would have, if anything, biased the results in favour of the latter. Another difference 433 
to highlight in the comparator group is the involvement of patients who were clozapine-naïve, whilst 434 
our IM clozapine cohort only had 18% of patients who had never taken clozapine before. It could be 435 
argued that the historical cohort covers a different timeframe compared to the IM clozapine cohort. 436 
Although this should be highlighted as a limitation, there hasn’t been any major recent 437 
implementation of clozapine-focused services in SLaM,  438 
 439 
Due to the retrospective nature of the study, we did not have standardised scales on side effects, 440 
nor could we collect data on patients’ subjective experience of IM clozapine treatment, which would 441 
have enhanced the study findings. Further research is needed to explore patients’ perspectives on 442 
IM treatment both at the time of administration and longer term. In particular, qualitative analysis 443 
would add to our understanding and reveal avenues for more focused quantitative work. Finally, 444 
future work should focus on which sub-groups of patients are more likely to benefit from IM clozapine 445 
prescription to support more targeted approaches to interventions.  446 
 447 
  448 
CONCLUSIONS 449 
 450 
The main finding of our study is that most of patients prescribed IM clozapine were able to 451 
successfully initiate oral clozapine after IM prescription, with half of patients not requiring 452 
administration of the injection. Discontinuation rates after initial IM clozapine prescription were 453 
consistent with current literature and similar to the comparison group. Discontinuation rates post 454 
discharge did not differ from those who were only prescribed oral treatment with clozapine from 455 
initiation. Our data, though preliminary, suggest that prescribing IM clozapine is a viable short-term 456 
tool to allow patients to access oral clozapine, the most effective available treatment for treatment-457 
resistant psychotic disorders. Pain and swelling at injection site were the only reported side effects 458 
specific to the IM formulation and occurred only in a minority of patients. Additional evidence, 459 
possibly derived from robust prospective studies, is needed to provide new and more definite insights 460 
about the transition from IM to oral formulations of clozapine.  461 
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Table 1. Demographic and clinical characteristics 482 
Characteristic 
IM clozapine cohort 
Comparison 
group 




















Male gender 26 (56) 10 (53) 12 (60) 102 (63) 
Ethnicity     
Caucasian 22 (56) 11 (58) 11 (55) 55 (34) 
African or Caribbean 14 (36) 8 (42) 6 (30) 73 (45) 
Others 3 (8) 0 3 (15) 33 (21) 
Age at IM clozapine prescription 
(years ± SD) 
46 ± 10.86 48 ± 9.25 44 ± 12.03 31 ± 11.54 
Length of illness (years ± SD) 21.32 ± 11.18 23 ± 12.08 19.63 ± 10.31 9.42 ± 8.01 
Diagnosis     
F20 Paranoid 
Schizophrenia 
18 (46) 9 (47) 9 (45) 154 (95) 
F32 Bipolar disorder / 
F25 Schizoaffective 
disorder* 
21 (54) 10 (52) 11 (55) 8 (5) 
CGI score at clozapine 
prescription (mean ± SD) 
6.18 ± 0.45 6.26 ± 0.45 6.10 ± 0.45 5.32 ± 0.66 
Hospital setting      
Acute ward 16 (41) 7 (37) 9 (45) na 
Psychiatric Intensive 
Care Unit 
8 (20) 5 (26) 3 (15) na 
National psychosis Unit 14 (36) 7 (37) 7 (35) na 
Forensic ward 1 (3) 0 (0) 1 (5) na 




9 (23) 5 (26) 4 (20) na 
Antidepressants 4 (10) 2 (11) 2 (10) na 
Mood stabiliser   9 (23) 4 (22) 5 (25) na 
Antihypertensive  13 (31) 6 (32) 7 (35) na 
Anticholinergic  7 (18) 2 (11) 5 (25) na 
            Other 23 (60) 12 (63) 11 (55) na 
Length of admission (days ± 
SD)** 
387.07±296.42 415.27 ± 281.16 369.83 ± 312.07 444.95 ± 712.21 
Length of admission after 
clozapine prescription (days ± 
SD)** 
280.07±225.41 232.18 ± 185.75 309.33 ± 246.98 239.16 ± 297.39 
No previous trial with clozapine 7 (18) 5 (26) 2 (10) 162 (100) 
 * Schizoaffective disorder and Bipolar disorder combined to avoid presenting identifiable data 483 































Table 2. Characteristics of IM clozapine administrations 515 
 516 
Characteristic Median (min-max) 
Number of days of injection 2 (1 - 56) 
Number of injections - 1 injection: 6 patients 
- 2 injections: 4 patients 
- 3 – 10 injections: 3 patients 
- >10 injections: 6 patients 
Maximum IM daily dose (mg) 75 (6.25 - 200) 
Physical restraints required (n, %) 9 (47) 
Number of restraints - 0 restraints: 10 patients 
- 1 restraint: 5 patients 
- >1 restraint: 4 patients 
Titration (n, %) 16 (84) 
IM administered consecutively (n,%) 7 (50) 
Patients who did not transition to oral clozapine (n,%) 3 (16) 




















Table 3. Results from the Cox regression analyses   536 
 537 
Cox regression analysis Hazard ratio (95%CI) Hazard Ratio adjusted for 
propensity scores (95%CI) 
IM clozapine cohort vs oral clozapine comparison group 
Clozapine discontinuation at 2-year follow-up 0.39 (0.19 – 0.80) 0.39 (0.14 – 1.06) 
Clozapine discontinuation at 1-year post-
discharge follow-up  
0.54 (0.23 - 1.28) 0.37 (0.11 - 1.24) 
Post-hoc analysis: IM clozapine administered vs non-administered  
Post-hoc analysis: Clozapine discontinuation 
at 2-year follow-up  
10.34 (CI 1.26 - 84.70) Not applicable 
Post-hoc analysis: Clozapine discontinuation 
at 1-year post- discharge follow-up  
























Fig. 1. Kaplan-Meier survival curves - A. Clozapine discontinuation rates after IM (IM cohort) or oral 561 
(comparison group) clozapine prescription. B. Post-hoc analysis of clozapine discontinuation rates 562 
after IM or oral (comparison group) clozapine prescription after subdividing patients according to 563 
whether they were administered and not administered IM clozapine. C. Clozapine discontinuation 564 
rates after discharge in the cohort and the comparison group. D. Clozapine discontinuation rates 565 
after discharge subdivided by whether IM clozapine was administered, versus the comparison group 566 
































































only oral clozapine  
 
n = 316 
Patients prescribed  
oral and IM clozapine 
 
n = 39 
Included in post-discharge 
survival analysis 
 
n = 162 
Excluded from survival 
analysis 
 
Patients not prescribed oral 
clozapine while detained under 
the Mental Health Act 
 
n = 154 
IM clozapine administered 
 
n = 19 
IM clozapine not administered 
 
n = 20 
Included in post-discharge 
survival analysis 
 
n = 27 
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discharge survival analysis 
 
Patients not discharged on 
clozapine (n = 2) 
 
Patients still admitted to 
hospital at data collection  
(n = 10) 
 
